The exosome diagnostic and therapeutic market is projected to grow at a CAGR of 9.1% from 2024 to 2034. Market valuation will increase from USD 88.56 million in 2024 to USD 211.6 million by 2034.
MBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available: Madison, Wisconsin Tuesday, January 7, 2025, 15:00 Hrs [IST] In a milestone for cel ...